464
Inmunoterapia
Allergol et inmunopathol. 2010; 38,
5: 259-62.
7 Abramson MJ, Puy RM, Weiner JM.
Allergen immunotherapy for asth-
ma. Cochrane Database Syst Rev
2003;(4): CD001186.
8 Calderon MA, Alves B, Jacobson M,
Hurwitz B, Sheikh A, Durham S. Aller-
gen injection immunotherapy for sea-
sonal allergic rhinitis. Cochrane Data-
base SystRev 2007;(1): CD001936.
9 Martin Penagos, MD, MSc; Giovanni
Passalacqua, MD; Enrico Compalati,
MD; Carlos E. Baena-Cagnani, MD;
Socorro Orozco, MD; Alvaro Pedro-
za, MD; and Giorgio Walter Canoni-
ca, MD. Metaanalysis of the Efficacy
of Sublingual Immunotherapy in
the Treatment of Allergic Asthma in
Pediatric Patients, 3 to 18 Years of
Age* CHEST / 133 / 3 / MARCH, 2008
10 Abramson MJ, Puy RM, Weiner
JM. Injection allergen immunothe-
rapy for asthma.
Cochrane Data-
base of Systematic Reviews
2010,
Issue 8. Art. No.: CD001186. DOI:
10.1002/14651858.CD001186.pub2.
11 Jacobsen L, Niggemann B, Dreborg
S, Ferdousi HA, Halken S, Høst A, et
al. The PAT investigator group. Spe-
cific immunotherapy has long-term
preventive effect of seasonal and pe-
rennial asthma: 10-year follow-up on
the PAT study. Allergy. 2007; 62: 943-8.
12 Cox L, Larenas-Linneman D, Lockey
F, Passalaqua G. Speaking the same
Languaje: The World Allergy Orga-
nization Subcutaneus Immunothe-
rapy Systemic reaction Grading
system. JJJ Allergy Clin Immunol
2010;125:569-74
13
/
14 P. Guardia. Recomendaciones para
el manejo de Inmunoterapia. Servi-
cio Andaluz de Salud. 2004.
www.
seaic.org/wp-content/.../download.
php?id=sas-inmunoterapia.
Debe informarse a los pacientes y/o a sus
padres sobre los posibles tratamientos de
su enfermedad, coste, duración y que le
aportará la inmunoterapia específica en
caso de estar indicada.
Bibliografía
1 Bousquet J, Lockey R, Malling HJ:
Allergen immunotherapy: thera-
peutic vaccines for allergic disea-
ses. AWHO position paper.J Allergy
Clin Immunol 1998, 102:558-62
2 Jutel M, Akdis CA. Immunological
mechanisms of allergen-specific
immunotherapy. Allergy 2011; 66:
725-732.
3 Alvaro M, Sancha J, Larramona H,
Lucas JM, Mesa M, Tabar AI, Marti-
nez-Cañavate A.
Allergen-specific
immunotherapy: Update on immu-
nological mechanisms.
Immunothe-
rapy Working Group; Sociedad Es-
pañola de Inmunología Clínica y
Alergia Pediátrica (SEICAP). Allergol
Immunopathol 2013;41(4):265-72
4 Scadding GW, Shamji MH, Jacobson
MR et al. Sublingual grass pollen
immunotherapy is associated with
increases in sublingual Foxp3-ex-
pressin cells and elevated allergen-
specific immunoglobulin G4, immu-
noglobulin A and serum inhibitory
activiy for immunoglobulin IgE-fa-
cilitated allergen binding to B cells.
Clin Exp Allergy 2010; 40: 598-606.
5 Francis JN, James LK, Paraskevo-
pouos G, et al. Grass pollen immu-
notherapy : IL-10 induction and su-
pression of late responses precede
IgG4 inhibitory activity. J allergy
Clin Immunol 2008; 121: 1120-1125
6 Martínez-Cañavate, A.I. Tabar, J.L.
Eseverri, F. Martın, C. Pedemonte-
Marco. An epidemiological survey
of hymenoptera venom allergy in
the Spanish paediatric population .
